Zhang Ke

Research areas : hip joint diseases, developmental dysplasia of the hip, hip and knee replacement; cutting-edge technologies: primary replacement of complex DDH, biomechanical research of joint prostheses;

Areas of expertise: Congenital hip dysplasia, avascular necrosis of the femoral head, and advanced osteoarthritis of the hip and knee; Academic highlights: A leading expert in complex hip replacement surgery in China, promoting the standardization and popularization of joint replacement in the country; Core value: Standardizing surgical strategies for high-difficulty DDH hip replacement and reducing complications of complex hip replacement.

Academician Qiao Jie

Founder and leader of the discipline, specializing in reproductive development and fertility protection

Research areas: Clinical and basic research related to obstetrics and gynecology and reproductive health; research on the mechanisms of early human embryonic development from the perspectives of genetics and epigenetics; preimplantation genetic diagnosis; pathogenesis of intractable infertility and optimization of assisted reproductive technologies.

Cutting-edge technology: Leading a team to conduct in-depth research on the mechanisms of early human embryonic development from the perspectives of genetics and epigenetics, successfully applying basic research findings to preimplantation genetic diagnosis. Revealing the pathogenesis of intractable infertility and optimizing assisted reproductive technologies. In 2023, as the first author, received the second prize of the National Natural Science Award ("Research on the Epigenetic Regulation Mechanisms and Intergenerational Transmission Laws of Human Reproductive Development"), unveiling the mysteries of two large-scale epigenetic remodelings of cell fate during human reproductive development.

Areas of expertise: Gynecological endocrinology, assisted reproductive technology, birth defects, polycystic ovary syndrome.

Academic Highlights and Core Values: Academician of the Chinese Academy of Engineering, Executive Vice President of Peking University, Director of the Peking University Health Science Center, Director of the Department of Obstetrics and Gynecology and Director of the Reproductive Medicine Center at Peking University Third Hospital. Chief Scientist of the Ministry of Science and Technology's "Major Project on Reproduction and Development," Changjiang Scholar Professor appointed by the Ministry of Education, and Chief Expert of the National Natural Science Foundation of China's Innovative Research Group on "Germic Cell Development." Chairman of the Third Committee of the Reproductive Medicine Branch of the Chinese Medical Association and Chairman of the First Committee of the Reproductive Medicine Professional Committee of the Chinese Medical Doctor Association. Published over 100 SCI articles as first or corresponding author in internationally renowned journals such as Nature, Lancet, Cell, and PNAS. Recipient of the Second Prize of the National Science and Technology Progress Award, the Ho Leung Ho Lee Science and Technology Progress Award, and the Wu Jieping-Paul Janssen Award, among others.

Professor Li Rong

Department Head, specializing in reproductive endocrinology and thin endometrium

Research areas: Reproductive endocrine disorders (polycystic ovary syndrome, primary ovarian insufficiency), female fertility assessment and protection, treatment of thin endometrium, and recurrent implantation failure in assisted reproductive technologies.

Cutting-edge technologies: First internationally reported the crucial role of elevated levels of autoimmune antibodies JO-1 and PR3 in the pathogenesis of primary ovarian insufficiency, and discovered that mitochondrial MT-CO1 gene mutations are one of the important causes of the disease. Led the world's first registered clinical trial, "Autologous fat vascular matrix component intrauterine perfusion for the treatment of thin endometrium," increasing the assisted pregnancy rate to 3% in women with damaged endometrium who do not respond to conventional treatments. Led the development of OvaRePred, the world's first AI tool for ovarian function assessment, which has been used by over 20,000 people in more than 42 countries and regions worldwide.

Areas of expertise: Polycystic ovary syndrome, female fertility assessment and protection, recurrent implantation failure in assisted reproductive technology treatment, and infertility.

Academic Highlights and Core Values: Chief Physician, Professor, Doctoral Supervisor, Vice President and Director of the Department of Reproductive Medicine at Peking University Third Hospital. Recipient of the National Science Fund for Distinguished Young Scholars, President-Elect of the Chinese Society of Reproductive Medicine, and Vice President of the Asia-Pacific Society for Reproductive Medicine. He has led multiple national key research projects, published 12 papers in top international journals such as Lancet and Nature, and edited 13 monographs; participated in the development of 2 international guidelines and spearheaded the development of 17 Chinese expert consensus and clinical guidelines; received numerous national and provincial-level honors, including the National Science and Technology Progress Award and the National Natural Science Award, and achieved 15 technology transfers. In 2022, he was awarded the title of "Capital Health Guardian."